The Trifluoromethyl Group as a Bioisosteric Replacement of the Aliphatic Nitro Group in CB<sub>1</sub> Receptor Positive Allosteric Modulators
作者:Chih-Chung Tseng、Gemma Baillie、Giulia Donvito、Mohammed A. Mustafa、Sophie E. Juola、Chiara Zanato、Chiara Massarenti、Sergio Dall’Angelo、William T. A. Harrison、Aron H. Lichtman、Ruth A. Ross、Matteo Zanda、Iain R. Greig
DOI:10.1021/acs.jmedchem.9b00252
日期:2019.5.23
(e.g., ZCZ011) featured a 3-nitroalkyl-2-phenyl-indole structure. Although a small number of drugs include the nitro group, it is generally not regarded as being "drug-like", and this is particularly true for aliphatic nitro groups. There are very few case studies where an appropriate bioisostere replaced a nitro group that had a direct role in binding. This may be indicative of the difficulty of replicating
第一代CB1阳性变构调节剂(例如ZCZ011)具有3-硝基烷基-2-苯基-吲哚结构。尽管少数药物包含硝基,但通常不认为它是“类药物”,对于脂肪族硝基尤其如此。在很少的案例研究中,适当的生物甾体替代了在结合中具有直接作用的硝基。这可能表明复制其结合相互作用的困难。在本文中,我们报道了针对CB1大麻素受体的变构结合位点的配体的设计和合成,其中CF3基团成功取代了脂肪族NO2。通常,带有CF3的化合物比它们的NO2当量更有效,并且还显示出改善的体外代谢稳定性。选择性能最佳平衡的CF3类似物(1)进行进一步的药理评估。体内试验研究表明(±)-1具有与(±)-ZCZ011相似的活性,两者在神经性疼痛的小鼠模型中均显示出有希望的功效。